Updated Jan 03, 2021 | 13:22 IST
The drug regulator has given a conditional nod to SII s Covishield and Bharat Biotech s Covaxin. Permission was also granted for Cadila Healthcare s Phase 3 trials. Representational Image
Drug Regulator accepts SEC s recommendations, gives conditional nod for Covishield, Covaxin
PM hails the nod for SII & Bharat Biotech vaccines as a decisive turning point in fight against COVID
2021 promises to the year of vaccination in India and elsewhere
Looking back, we didn’t know what was coming when 2020 descended upon us. While the whispers of a virus spreading in Wuhan were reported in earnest by the wires, they did not cause a storm, not then.
URL copied
Expert panel recommends granting restricted emergency use approval for COVAXIN.
A day after a government panel recommended to grant emergency use approval for the Oxford-AstraZeneca s Covishield vaccine for coronavirus, an expert panel on Saturday recommended granting permission for restricted emergency use authorisation for Bharat Biotech s indigenously developed COVID-19 vaccine â Covaxin, ANI reported quoting government sources.
The Subject Expert Committee of Central Drug Standard Control Organization on Saturday recommended Bharat Biotech s Covaxin for emergency use in India. The
final decision on its approval will, however, be taken by the Drug Controller General of India (DCGI).
The committee of experts assessing Coronavirus vaccines had called Hyderabad-based Bharat Biotech for a meeting in the afternoon today, a day after the firm was asked to present more data to get a nod, a top source said on Saturday.